European House Dust Mite (Der p 20) IgE Test · Blood

If you have severe eczema, year-round congestion, or asthma that flares at home, a dust mite allergy may be part of the story. Standard dust mite testing checks a few major components and can miss the broader pattern that drives the worst symptoms.

This test looks at one piece of that broader pattern. Knowing your level helps clarify whether you have a deep, complex dust mite allergy that may behave differently from a simple cat or pollen allergy.

What This Test Actually Measures

Der p 20 (a specific protein made by the European house dust mite) belongs to a family of allergens called arginine kinases. When your immune system overreacts to dust mite exposure, your B cells (a type of white blood cell that makes antibodies) produce IgE (immunoglobulin E, the antibody class that drives allergic reactions) that latches onto this protein. The test measures how much of that allergy antibody is circulating in your blood.

This is a component-resolved test, meaning it isolates your reaction to one specific mite protein rather than to the whole mite extract. Most routine dust mite blood tests measure reactions to Der p 1, Der p 2, and sometimes Der p 23. Der p 20 is not yet part of standard panels, which is part of why it carries useful information that broader tests can miss.

Why This Marker Matters: A Severity Signal

Der p 20 is best understood as a signal of how broad and severe your dust mite allergy has become, not as a basic yes-or-no test for whether you are allergic to mites. People with more advanced or complex atopic disease tend to recognize more mite proteins, and Der p 20 is often one of them.

This is a research-stage marker. There are no standardized clinical cutoffs, and a single reading should be interpreted alongside your symptoms, other dust mite component results, and overall allergic profile.

Atopic Dermatitis (Severe Eczema)

The strongest link for Der p 20 IgE is to severe atopic dermatitis, the chronic, intensely itchy form of eczema. In a study of 384 dust mite-allergic patients, sensitization to Der p 20 was more common in people with eczema than in those who only had hay fever, and very high levels were associated with severe eczema in the majority of those patients.

Put simply, if your Der p 20 IgE is high, it suggests your dust mite allergy is the kind that tracks with skin disease, not just nasal symptoms. That has practical consequences for how aggressively you should pursue allergen avoidance, skin barrier care, and consideration of immunotherapy.

Asthma and Multi-Organ Allergic Disease

Der p 20 rarely shows up alone. It tends to appear in people whose immune system has spread its attention across many mite proteins, what allergists call polysensitization. In the same 384-patient study, having IgE to more than three mite components, including Der p 5, 20, and 21, was associated with asthma and eczema, suggesting Der p 20 is part of a high-risk molecular pattern.

This matters because broader mite IgE patterns also predict downstream outcomes. In separate research, high overall dust mite IgE in blood was associated with a higher rate of progression from allergic rhinitis to asthma over five years, and high mite-specific IgE in children with allergic conjunctivitis predicted a greater risk of other allergic conditions.

What This Test Reveals That Standard Tests Miss

A standard dust mite blood test or skin prick test tells you whether your immune system reacts to dust mites in general. It does not distinguish between someone with mild seasonal sniffles and someone whose immune system has spread its reactions across many mite proteins. Even combined, skin prick and standard IgE tests have a positive predictive value of only about 0.7 against the gold-standard nasal provocation test.

Der p 20 IgE adds depth. It is not a better yes-or-no test for dust mite allergy. It is a phenotyping tool that helps answer: how complex is my dust mite allergy, and how likely is it to affect my skin and lungs, not just my nose?

Implications for Immunotherapy

Allergen immunotherapy, in which gradually increasing doses of allergen are given to retrain the immune system, works best for people whose IgE is dominated by the major mite allergens Der p 1 and Der p 2. People with broader IgE repertoires that include components like Der p 5, 7, and 21 tend to have poorer clinical responses, implying more complex disease that may need more tailored management.

Der p 20 belongs to that same category of additional components. A high level can prompt a conversation with an allergist about whether standard immunotherapy is the right approach for you or whether your case requires more individualized planning.

Why a Single Reading Is Not Enough

IgE responses to specific allergens evolve over time, especially in childhood and across the first two decades of life. They also shift with allergen exposure, treatment, and aging. One reading is a snapshot. Tracking your level gives you a trajectory.

A practical cadence: get a baseline now, retest in 6 to 12 months if you start allergen immunotherapy or change your environment significantly (new home, new bedding strategy, new pet), and at least every 1 to 2 years if you have ongoing eczema, asthma, or rhinitis symptoms. If your level is climbing alongside worsening symptoms, that pattern is more actionable than any single number.

What to Do With an Unexpected Result

A markedly elevated Der p 20 IgE result is a prompt to look at your full allergy workup rather than focus on this one number. Consider pairing it with a broader dust mite component panel (Der p 1, Der p 2, Der p 23) and total IgE to understand the full molecular pattern. If you have eczema, an allergist or dermatologist can help connect the dots between your skin and your allergy profile.

A low or undetectable Der p 20 IgE does not rule out dust mite allergy. Many dust mite-allergic people have IgE only to the major components Der p 1 and Der p 2. If your symptoms persist despite normal-looking standard testing, ask about a full component panel rather than assuming dust mites are not the trigger.

When Results Can Be Misleading

• Recent biologic therapy: dupilumab, a medication used for severe eczema and asthma, can lower allergen-specific IgE levels over many months without changing your underlying allergy. Omalizumab (an anti-IgE drug) also changes how IgE is measured. If you are on these, your result reflects treatment, not baseline allergy status.
• Allergen immunotherapy: if you are already receiving dust mite immunotherapy, your mite-specific IgE levels will shift over the course of treatment and should be interpreted in that context.
• Geographic and cross-reactivity factors: Der p 20 is an arginine kinase, which exists in similar form in cockroach and shellfish proteins. A high result may partly reflect cross-reactivity with these other allergens.
• Single-snapshot variability: IgE levels can drift over months. A borderline result is best confirmed with a repeat test before drawing strong conclusions.